EXAS250516P45000
- 1.77
- -0.78-30.59%
Exact Sciences Newsroom
Craig-Hallum Maintains Exact Sciences(EXAS.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Phathom Pharmaceuticals (PHAT) and Exact Sciences (EXAS)
Exact Sciences' Stock Resilience and Legal Outlook Drive Buy Rating
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $75
Bernstein Reaffirms Their Buy Rating on Exact Sciences (EXAS)
Exact Sciences Is Maintained at Overweight by Barclays
Mizuho Initiates Exact Sciences at Outperform With $60 Price Target
Exact Sciences Price Target Announced at $60.00/Share by Mizuho
Exact Sciences Initiated at Outperform by Mizuho
Exact Sciences Analyst Ratings
Barclays Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $55
Barclays Sticks to Its Buy Rating for Exact Sciences (EXAS)
Mizuho Securities Initiates Exact Sciences(EXAS.US) With Buy Rating, Announces Target Price $60
RBC Capital Maintains Exact Sciences(EXAS.US) With Hold Rating, Maintains Target Price $52
RBC Capital Remains a Hold on Exact Sciences (EXAS)
Strategic Developments and Product Launch Drive Buy Rating for Exact Sciences
Wells Fargo Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $63
Guggenheim Maintains Exact Sciences(EXAS.US) With Buy Rating, Announces Target Price $60
Benchmark Co. Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $65
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $80